Navigation Links
Centaur Animal Health Appoints New President and Chief Executive Officer.
Date:8/27/2013

KANSAS CITY, Kan. and PHILADELPHIA, Aug. 27, 2013 /PRNewswire/ -- Centaur Animal Health, is pleased to announce the appointment of Jeffrey Boily as President, CEO, and Director effective September 1, 2013.

Mark Metrokotsas, who has been the CEO, will become Chairman of Centaur's Board of Directors.

Boily brings over 30 years of global life sciences experience in pharmaceuticals, biotechnology, drug delivery and animal health and will be instrumental in accelerating plans toward Centaur becoming a major animal health company. Centaur has established a track record of successful execution on product initiatives and is aggressively looking to in-license additional products.

"I'm delighted to lead Centaur Animal Health as we embark on the next phase of growth," said Boily.

"Jeff's background as an entrepreneurial leader and his experience in fund-raising and partnering with large and small firms is a perfect fit for Centaur," said Mark Metrokotsas, Board Chair for Centaur Animal Health.

Jeffrey Boily is non-executive Chairman of ProteaPex Therapeutics, a firm researching and developing innovative animal health therapeutics. Most recently he was President and CEO of the Center for Animal Health Innovation which focused on identifying and funding breakthrough technologies. Previous to this, he was CEO of BioWizard, a VC funded research and information firm for biomedical scientists. He gained large company executive experience at Abbott, Rogers and Wyeth including Fort Dodge Animal Health. He holds an M.B.A. from the John Molson School of Business, Concordia U., Montreal and a B.S. in biology from the U. of Ottawa. He also serves on the Board of Directors of various healthcare companies.

About Centaur Animal Health

Centaur Animal Health is focused on developing innovative diagnostics, pharmaceuticals and nutraceuticals that address significant therapeutic needs for companion and production animals. Centaur licenses patent-protected technologies acquired from animal health or human pharmaceutical and biotechnology companies. Contract manufacturing is available in their FDA certified plant. For more information, please visit www.centauranimalhealth.com

For Media:
Jeffrey Boily
Centaur Animal Health
O: (484) 619-3685
Jeff.Boily@centauranimalhealth.com
Web Site: http://www.centauranimalhealth.com


'/>"/>
SOURCE Centaur Animal Health
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
2. Henry Schein to Open NASDAQ Stock Market to Celebrate Rebranding of U.S. Animal Health Business
3. Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimers Disease Through the PI3k-Akt Pathway
4. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
5. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
6. Masimo Signs Far-Reaching Pulse Oximetry Distribution Deal with Butler Schein Animal Health
7. Small Animal Imaging (In Vivo) Market - By systems and reagents - Competitive Analysis & Global Forecasts to 2017
8. McCord Animal Health Introduces Board of Advisors
9. Peter Dinklage Joins Cruelty Free International to Call for US ban on Animal Tests for Cosmetics
10. Star Scientific and Rock Creek Pharmaceuticals Report on the Beneficial Nutritional Effects of Anatabine in an Animal Model of Ulcerative Colitis
11. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... ... its executive team as the President of its HealthBI division. McFarland will ... and contact centers. , “Scott is a utility player who balances his ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced a ... When we’re born, Nature gives us a full supply of melanin – in the ... lose this natural glare-reducing pigment; however, around the age of thirty, we develop a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... the present, Mirixa Corporation recently unveiled the MirixaPro 6.0 platform. As the ... how medication management services are delivered. Based on industry research and market ...
(Date:9/19/2017)... ... September 19, 2017 , ... Back Pain Centers of ... back pain with a reputable physician in their area, announces the addition of ... as Nevada Spine Clinic was founded by board-certified spine surgeon, Jaswinder Grover, M.D. ...
(Date:9/19/2017)... ... 2017 , ... The ISO 9001 standard sets out the requirements for a ... and improve customer satisfaction. ISO 9001:2015 was released in 2015 and certified organizations have ... September 2018. , As described in this white paper , ISO ...
Breaking Medicine News(10 mins):